Skye Bioscience (NASDAQ:SKYE - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06, Zacks reports. During the same quarter in the prior year, the firm posted ($0.36) earnings per share.
Skye Bioscience Price Performance
NASDAQ:SKYE traded up $0.10 during trading hours on Monday, reaching $2.35. The company's stock had a trading volume of 205,898 shares, compared to its average volume of 213,597. The company has a market capitalization of $71.29 million, a price-to-earnings ratio of -3.26 and a beta of 1.71. The firm's 50-day moving average price is $2.66. Skye Bioscience has a 1 year low of $1.83 and a 1 year high of $17.65.
Wall Street Analysts Forecast Growth
SKYE has been the subject of several recent analyst reports. Craig Hallum reduced their target price on Skye Bioscience from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Friday. William Blair reissued an "outperform" rating on shares of Skye Bioscience in a report on Friday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $18.00.
Check Out Our Latest Report on SKYE
About Skye Bioscience
(
Get Free Report)
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Featured Articles
Before you consider Skye Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skye Bioscience wasn't on the list.
While Skye Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
